<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590898</url>
  </required_header>
  <id_info>
    <org_study_id>CVC-002</org_study_id>
    <nct_id>NCT04590898</nct_id>
  </id_info>
  <brief_title>Peri-device Leakage Closure After LAAO</brief_title>
  <official_title>Safety and Feasibility of Peri-device Leakage Closure After Left Atrial Appendage Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Center Frankfurt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Center Frankfurt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators thought to evaluate the safety and feasibility of peri-device leakage&#xD;
      closure after left atrial appendage occlusion (LAAO, either surgical or interventional) with&#xD;
      different devices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The global burden of atrial fibrillation (AF) is high and thromboembolic stroke may be one of&#xD;
      the fatal complications. Oral anticoagulation has been the mainstay therapy for decades to&#xD;
      mitigate stroke risk. However, in poor candidates for long-term anticoagulation&#xD;
      non-pharmacological stroke prevention with percutaneous left atrial appendage occlusion&#xD;
      (LAAO) is a considerable treatment option. LAA shape and size varies widely and incomplete&#xD;
      LAA closure or new leaks, due to LAA remodeling after the procedure, are observed in up to&#xD;
      30% of patients. Those leaks may cause turbulent flow and increase the risk for thrombus&#xD;
      formation and subsequent thromboembolic events. However, the clinical significance after&#xD;
      percutaneous LAAO has yet to be determined.&#xD;
&#xD;
      If significant leaks are present, patients usually remain on oral anticoagulation. In very&#xD;
      few cases, an interventional approach is used to close peri-device leaks.&#xD;
&#xD;
      This is the first systematic study, trying to include a respectable number of patients who&#xD;
      underwent peri-device leakage closure after LAAO. In this multi-center, collaborative study&#xD;
      the investigators aim to identify different peri-device leak closure strategies with&#xD;
      associated clinical outcomes and evaluate safety and feasibility of the procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural mortality</measure>
    <time_frame>In-hospital stay, assessed up to 30days</time_frame>
    <description>Rate of all-cause mortality during the index procedure, number of participants experiencing a procedure-related death within 30days or during in-hospital stay for the index procedure (if&gt;30days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure-related clinically relevant pericardial effusion</measure>
    <time_frame>In-hospital stay, assessed up to 30days</time_frame>
    <description>Number of participants experiencing pericardial effusion with hemodynamic relevance, treated with therapeutic pericardiocentesis or surgical intervention, requiring blood transfusion or resulting in shock and/or death, which was procedure related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure-related ischemic stroke</measure>
    <time_frame>In-hospital stay, assessed up to 30days</time_frame>
    <description>Number of participants experiencing an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, which was procedure related</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of participants experiencing bleeding complications evaluated by using VARC-2 criteria with LAAO specific modifications (after the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular access site complications</measure>
    <time_frame>during procedure, assessed up to 7 days</time_frame>
    <description>Number of participants experiencing retroperitoneal haematoma, AV-fistula, arterial complications, venous complications, symptomatic peripheral ischemia, nerve injury with clinical symptoms &gt;24h, vascular surgical repair at access site, pulmonary embolism, ipsilateral deep vein thrombosis, access site-related infection requiring iv. antibiotics or extended hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver- and kidney failure associated with the procedure</measure>
    <time_frame>In-hospital stay, assessed up to 30days</time_frame>
    <description>Number of participants experiencing liver- and kidney failure potentially associated with the procedure evaluated by using the definitions of Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-associated complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of participants experiencingdevice migration, perforation, laceration, erosion, device infection, pericarditis, device-related thrombus and persistent or occurrence of new peri-device leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke or transitory ischemic attack</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of participants experiencing an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue not directly related to the procedure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <condition>Bleeding</condition>
  <condition>Leakage of Cardiac Device</condition>
  <arm_group>
    <arm_group_label>significant peri-device leakage after LAA occlusion</arm_group_label>
    <description>Peri-device leakage closure after left atrial appendage occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peri-device leakage closure after left atrial appendage occlusion</intervention_name>
    <description>Peri-device leakage closure after left atrial appendage occlusion</description>
    <arm_group_label>significant peri-device leakage after LAA occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after interventional or surgical left atrial appendage occlusion with severe&#xD;
        leakage, who underwent interventional peri-device leakage closure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients after interventional or surgical left atrial appendage occlusion with severe&#xD;
             leakage, who underwent interventional peri-device leakage closure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  n/a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Piayda</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Düsseldorf and Cardio Vascular Center Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine de Bruijn</last_name>
    <phone>+49 69 9794 7653</phone>
    <email>s.debruijn@cvcfrankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Piayda</last_name>
    <phone>+49 69 4603 1344</phone>
    <email>kerstinpiayda@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>• Banner University Medical Center Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Heart Rhythm Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital - Saint Mary's Campus</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Heart Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardio Vascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine de Bruijn</last_name>
      <phone>+496997947653</phone>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Piayda</last_name>
      <phone>+496946031344</phone>
      <email>kerstinpiayda@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Horst Sievert</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerstin Piayda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Campus Benjamin Franklin (CBF)</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>61701</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuffield Health</name>
      <address>
        <city>Headington</city>
        <zip>OX3 7RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>left atrial appendage occlusion</keyword>
  <keyword>peri-device leakage</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

